Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Argentine Stop Trial (AST)
NCT05926128Unknown
- Sponsor
- Fundaleu
- Start
- Feb 2019
- Primary completion
- Jun 2022
- Countries
- 1
01
Overview
Open-label, single-arm trial in chronic myeloid leukemia (CML), sponsored by Fundaleu. Primary endpoint: Molecular Relapse Free Survival at 24 months. Status: unknown.
02
Conditions
chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT05926128.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05926128.